Cargando…
Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer
Despite some limitations such as long-term side effects or the potential presence of intrinsic or acquired resistance, platinum compounds are key therapeutic components for the treatment of several solid tumors. To overcome these limitations, maintaining the same efficacy, organometallic ruthenium(I...
Autores principales: | Domínguez-Jurado, Elena, Cimas, Francisco J., Castro-Osma, José Antonio, Juan, Alberto, Lara-Sánchez, Agustín, Rodríguez-Diéguez, Antonio, Shafir, Alexandr, Ocaña, Alberto, Alonso-Moreno, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539368/ https://www.ncbi.nlm.nih.gov/pubmed/34683852 http://dx.doi.org/10.3390/pharmaceutics13101559 |
Ejemplares similares
-
Screening and Preliminary Biochemical and Biological
Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF(4)] in Breast Cancer Models
por: Corrales Sánchez, Veronica, et al.
Publicado: (2019) -
N,N-Bis(diphenylphosphino)ethylamine
por: Cloete, Nicoline, et al.
Publicado: (2009) -
p-Cymene Complexes of Ruthenium(II) as Antitumor Agents
por: Pujante-Galián, María Angeles, et al.
Publicado: (2020) -
[N,N-Bis(diphenylphosphino)isopropylamine]dibromidonickel(II)
por: Hapke, Marko, et al.
Publicado: (2009) -
(η(6)-p-Cymene)bis(trichloridostannyl)(triethoxyphosphine-κP)ruthenium(II)
por: Shapovalov, Sergey S., et al.
Publicado: (2009)